Olson et al., 2004 - Google Patents
Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 X Anti-EGFROlson et al., 2004
- Document ID
- 4941472081669486531
- Author
- Olson S
- Davol P
- Lum L
- Publication year
- Publication venue
- Journal of Immunotherapy
External Links
Snippet
Gustavo Moviglia, Gabriela Varela, Carlos Gaeta, Andrea Paes de Lima, Pablo Farina, Hernan Costanzo, Roberto Moya, Silvia Merino. Cell Therapy, Regina Mater Foundation, Buenos Aires, Capital Federal, Argentina; Tissue Culture Laboratory, Regina Mater …
- 208000005017 Glioblastoma 0 title abstract description 19
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210214436A1 (en) | Multi-specific binding proteins and improvements thereon | |
| KR102721494B1 (en) | Composition for supporting anti-cancer T cell therapeutic agent comprising depleting anti-CD4 monoclonal antibody and use thereof | |
| JP2018197247A (en) | Pharmaceutical composition comprising il-12 and agent for blockade of t-cell inhibitory molecules for tumor therapy | |
| US9238064B2 (en) | Allogeneic cancer cell-based immunotherapy | |
| IL108501A (en) | Antibodies and pharmaceutical compositions containing them | |
| JP2018506520A (en) | Combination preparation for treating cancer or infection | |
| TW202005985A (en) | Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies | |
| EP3091999B1 (en) | Improved cell compositions and methods for cancer therapy | |
| CN106554416B (en) | A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor | |
| US20230139492A1 (en) | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer | |
| JP2022542443A (en) | Anti-BCMA CAR T cells for treatment of multiple myeloma | |
| CN115843255A (en) | CD22 targeting moieties for the treatment of B cell type acute lymphoblastic leukemia (B-ALL) | |
| WO2021062332A1 (en) | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer | |
| Mukherjee et al. | Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model | |
| Olson et al. | Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 X Anti-EGFR | |
| CN117693350A (en) | Combination of checkpoint inhibitors with oncolytic viruses for the treatment of cancer | |
| CN112439060B (en) | New use of PD-L1 immunotherapy | |
| Popescu et al. | DC1-Based Protocols for Adoptive Immunotherapy for PTLD Boost Type-1 Anti-EBV CD8+ T Cell Responses in Solid Organ Tranplant Patients | |
| US20230036135A1 (en) | Bcg car constructs and methods of their manufacture and use | |
| Zhang | Cancer Immunotherapy | |
| TWI790193B (en) | Methods and antibodies for modulation of immunoresponse | |
| US20230235089A1 (en) | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies | |
| WO2024060140A1 (en) | Egfrviii chimeric antigen receptor and use thereof | |
| Muthumani et al. | 401. In Vivo Expression of Plasmid Encoded IgG for PD-1 or LAG3 by Synthetic DNA as a New Tool for Cancer Immunotherapy | |
| Sutton et al. | 402. Bioengineering of Peripheral Blood Derived Gamma Delta T Cells in a Serum-Free Expansion Medium |